Je was op zoek naar: all cause (Engels - Maltees)

all cause death
mewt kull kawża

all-cause death
mewt mill-kawżi kollha

death (all-cause)
mewt (kull kawża)

vte or all-cause death
vte jew mewt mill- kawżi kollha

total vte/all-cause death
vte totali/mewta b’kull kawża

all cause mortality at 3 years
mortalità minn kull kawża wara 3 snin

all-cause death, mi or stroke
mewt minn kull kawża, mi jew puplesija

recurrent symptomatic vte and all- cause deaths
vte sintomatika rikorrenti u mwiet mill-kawżi kollha

hospitalization and ed visits due to all cause gastroenteritis
rikoverar fl-isptar u visti fl-ed minħabba gastroenterite minn kull kawża

the primary endpoint was time to all-cause mortality.
ir - riżultat tat- tmiem l- aktar importanti kien iż- żmien sa mortalità minn kull kawża.

no benefit was observed for mace or all cause mortality .
ma ġiex osservat benefiċċju għal mace jew mortalità minn kull kawża .

no benefit was observed for mace or all-cause mortality.
ma ġie osservat ebda benefiċċju għal mace jew għall-mortalità b’kull kawża.

all cause mortality, mi (excl. silent mi), or stroke
mewt bil-kawżi kollha, mi (eskluż mi silenzjuż), jew attakk ta’ puplesija

all-cause mortality by day 28 was 10/35 (28.6%).
il-mortalità mill-kawżalità kollha sat-28 Ġurnata kienet ta’ 10/35 (28.6%).

the primary endpoint of this prospective study was the all-cause mortality.
il- punt ta ’ riferiment aħħari prinċipali ta ’ dan l- istudju kienet il- mortalità ta ’ kull kawża.

data for the total vte and all cause mortality endpoint are shown in table 11.
dejta għall-vte totali u r-riżultat aħħari tal-mortalità mill-kawżi kollha, huma murija f’tabella 11.

all-cause mortality rate was not significantly different between the two treatment groups.
ir- rata ta ’ mortalità għal kull kawża ma kinetx sinifikament differenti bejn iż- żewġ gruppi ta ’ trattament.

selective inclusion of one secondary endpoint- all cause mortality- is not recommended.
l- inklużjoni selettiva ta ’ endpoint sekondarju - mortalità minn kwalunkwe kawża - mhijiex rakkomandata.

in this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by
il- benefiċċji għall- morbidità kienu l- akbar f’ sottogrupp ta ’ pazjenti li ma kienux qed jirċievu inibitur ta ’ ace (n=366).

the number of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year vs.
fil-grupp ta’ pazjenti trattati b’adalimumb in-numru ta’ dħul fl- isptar minħabba kwalunkwe kawża kien 0.18 għal kull sena ta’ pazjent vs.